Original Article
Risk of Fracture after Androgen Deprivation for Prostate Cancer
N Engl J Med 2005; 352:154-164January 13, 2005
- Abstract
Background
The use of androgen-deprivation therapy for prostate cancer has increased substantially over the past 15 years. This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied.
Methods
We studied the records of 50,613 men who were listed in the linked database of the Surveillance, Epidemiology, and End Results program and Medicare as having received a diagnosis of prostate cancer in the period from 1992 through 1997. The primary outcomes were the occurrence of any fracture and the occurrence of a fracture resulting in hospitalization. Cox proportional-hazards analyses were adjusted for characteristics of the patients and the cancer, other cancer treatment received, and the occurrence of a fracture or the diagnosis of osteoporosis during the 12 months preceding the diagnosis of cancer.
Results
Of men surviving at least five years after diagnosis, 19.4 percent of those who received androgen-deprivation therapy had a fracture, as compared with 12.6 percent of those not receiving androgen-deprivation therapy (P<0.001). In the Cox proportional-hazards analyses, adjusted for characteristics of the patient and the tumor, there was a statistically significant relation between the number of doses of gonadotropin-releasing hormone received during the 12 months after diagnosis and the subsequent risk of fracture.
Conclusions
Androgen-deprivation therapy for prostate cancer increases the risk of fracture.
Media in This Article
Figure 1
Unadjusted Fracture-free Survival among Patients with Prostate Cancer, According to Androgen-Deprivation Therapy.Table 1
Characteristics of the Patients.Article Activity
- Article
Androgen-deprivation therapy for prostate cancer can reduce morbidity, palliate metastases, and improve survival in locally advanced disease when combined with radiation.1-3 However, androgen-deprivation therapy alone, in the form of gonadotropin-releasing hormone agonists, is increasingly being used in men with localized prostate cancer (cancer confined to the prostate) and in men in whom the level of prostate-specific antigen (PSA) rises after prostatectomy4-6 — both situations in which most patients are minimally symptomatic and no survival benefit has been demonstrated.1,7 For these reasons, it is important to have accurate data on the toxic effects of androgen deprivation.8,9 Bone fractures are of particular concern, given their association with increased mortality in prostate cancer.10
A rapid loss of bone-mineral density occurs within the first 6 to 12 months of androgen-deprivation therapy.11,12 However, the assessment of the risk of fracture associated with this treatment has been limited in previous studies by small numbers and the lack of a control group.13-16 We used the linked database of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and Medicare to assess the risk of fracture associated with androgen deprivation in the form of orchiectomy or treatment with gonadotropin-releasing hormone agonists in a large population-based sample of men who received the diagnosis of prostate cancer during the period from 1992 through 1997.
Methods
The study protocol was approved by the local institutional review board; because of the study design, the requirement of informed consent was waived.
Data Sources
The SEER–Medicare database links two large population-based sources of data that together provide information on older adults with newly diagnosed cancer.17 During the 1990s, the SEER program consisted of a group of 11 tumor registries that represented approximately 14 percent of the population.
Study Subjects
Data on all men 66 years of age or older who received a first diagnosis of prostate cancer in the years from 1992 through 1997 were selected, for a total of 92,474 subjects. To ensure complete information, we excluded patients who were not enrolled in both Part A and Part B Medicare for the 12 months before the diagnosis and the 12 months after the diagnosis (13,352 cases), were members of a health maintenance organization (17,275 cases), or whose disease had been diagnosed on autopsy or on a death certificate (1076 cases). We limited the comparisons to men with prostate cancer who received at least one dose of a gonadotropin-releasing hormone agonist or underwent orchiectomy within six months after receiving the diagnosis with those with prostate cancer who received neither type of treatment at any time after diagnosis. This limitation excluded 10,158 patients who had started treatment with gonadotropin-releasing hormone agonists or had undergone orchiectomy six months or more after diagnosis. We also performed an analysis that included all patients who received androgen-deprivation therapy during the first 24 months after diagnosis, and this analysis did not substantially alter our results. Overall, data were available for a total of 50,613 patients for the primary sample, with follow-up through 2001.
The variables used in this study are defined in the Supplementary Appendix, which is available with the full text of this article at www.nejm.org.18-28 The primary outcomes were any fracture and fracture resulting in hospitalization. Secondary outcomes were a new diagnosis of osteoporosis and fractures at specific sites.
Statistical Analysis
The chi-square test was used to compare the proportions of patients who were treated with androgen deprivation according to different categories of baseline characteristics and to compare the proportions of patients with bone-related toxic effects according to the presence or absence of androgen-deprivation therapy. The Kaplan–Meier method was used to generate estimates of unadjusted, fracture-free survival. Survival analyses were performed with the use of Cox proportional-hazards regression. The dependent variable was either the time to a first fracture or the time to a first fracture that resulted in hospitalization, depending on the outcome being analyzed. Patients were censored at death, the loss of coverage under Medicare Part A or Part B, or a change to coverage under a health maintenance organization. An examination for interaction between prespecified variables of interest (age, cancer stage, race, and score on a modified form of the Charlson comorbidity index18,19) and the presence or absence of androgen-deprivation therapy on the relative risk of fracture was performed with the use of a Cox model. Race was determined on the basis of the codes for racial and ethnic groups used in the SEER database.
The numbers needed to harm were calculated by taking the inverse of the difference between the rates of fracture adjusted in the Cox model at five years after diagnosis for the group that did not receive androgen-deprivation therapy and the group that did receive it. Although numbers needed to harm are usually reserved for the analysis of clinical trials, we use them here to provide a measure of the absolute effect of androgen-deprivation therapy on the risk of fracture. All analyses were performed with the use of SAS software (version 8.2) (SAS Institute).
Results
Proportion of Patients Receiving Study Treatment
Table 1Table 1
Characteristics of the Patients. presents the percentages of 50,613 men 66 years of age or older with prostate cancer who received androgen-deprivation therapy (in the form of either gonadotropin-releasing hormone agonists or orchiectomy) within six months after diagnosis as a function of the characteristics of the patients and the cancer. The rate of use of androgen-deprivation treatment increased with increasing age, the stage of the cancer at diagnosis, the grade of prostate cancer, and the presence of coexisting conditions. In addition, there was an increase in the use of androgen-deprivation therapy over the period from 1992 to 1997, and the lowest to the highest rates of use among the SEER geographic regions differed by a factor of two.Proportion of Patients with Bone-Related Toxic Effects
The rates of occurrence of various bone-related toxic effects during the 12 months before the diagnosis of prostate cancer and during the period of 12 to 60 months after diagnosis were compared between the group that received androgen-deprivation therapy and the group that did not (Table 2Table 2
Proportions of Patients with Bone-Related Toxic Effects before and after the Diagnosis of Prostate Cancer, According to the Presence or Absence of Androgen-Deprivation Therapy.). To ensure complete follow-up, data on patients who died or lost coverage under Medicare Part A or Part B during the 60 months after diagnosis were excluded. In addition, data on patients with bone-related toxic effects that occurred during the first 12 months after diagnosis were excluded, because these outcomes were considered unlikely to be related to the therapy (and reanalysis including these patients did not substantially alter the results).There was a small but statistically significant increase in the proportion of patients with any fracture during the 12 months before diagnosis in the group that received androgen-deprivation therapy as compared with the group that did not receive androgen-deprivation therapy. All bone-related toxic effects developed significantly more frequently during the 12 to 60 months after diagnosis in the androgen-deprivation group. During this period, 19.4 percent of those in the androgen-deprivation group had a fracture, as compared with 12.6 percent of those not receiving the study treatment (P<0.001). In the same four-year period, 5.2 percent of those treated with androgen-deprivation therapy were hospitalized with a fracture, as compared with 2.4 percent of those not treated (P<0.001).
We repeated the analysis shown in Table 2, restricting it to data on patients with stage I, II, or III disease according to the criteria of the American Joint Committee on Cancer (AJCC) and low-grade or moderate-grade prostate cancer. The results of the two analyses were similar. For example, the rate of hospitalization with fracture in the latter analysis was 4.9 percent among patients who received androgen-deprivation therapy as compared with 2.2 percent among those who did not (P<0.001).
Unadjusted Fracture-Free Survival
The Kaplan–Meier method was used to generate unadjusted estimates of survival free of any fracture among the groups that did or did not receive androgen-deprivation therapy (Figure 1Figure 1
Unadjusted Fracture-free Survival among Patients with Prostate Cancer, According to Androgen-Deprivation Therapy.). All subjects who survived at least 12 months after the diagnosis of prostate cancer were included in the analysis. Androgen-deprivation therapy was divided between those who underwent orchiectomy and those who received gonadotropin-releasing hormone agonists, stratified according to the number of doses received (one to four, five to eight, or nine or more doses) in the year after diagnosis. Patients who had fractures in the first year after diagnosis were excluded. Those who underwent orchiectomy and those who received nine or more doses of gonadotropin-releasing hormone agonists in the year after diagnosis had the lowest rates of fracture-free survival. The curves for the groups that underwent orchiectomy or received five to eight doses or nine or more doses of gonadotropin-releasing hormone agonists diverged from that for the group that did not receive androgen-deprivation therapy over the entire period of follow-up.Fracture Risk and Androgen-Deprivation Therapy
The risk of any fracture associated with androgen-deprivation therapy was assessed with the use of a Cox regression model adjusted for variables related to the patient and the cancer, other cancer treatment received, and a diagnosis of fracture, osteoporosis, or osteopenia during the year before the diagnosis of cancer (Table 3Table 3
Risk of Fracture Associated with Androgen-Deprivation Therapy.). Patients who died during the year after diagnosis or who had fractures during those 12 months were excluded. Subjects were followed for a mean of 5.1 years after diagnosis.The relative risk of the occurrence of any fracture or a fracture that resulted in hospitalization increased steadily with the increasing number of doses of a gonadotropin-releasing hormone agonist received during the first year after diagnosis (P<0.001 for linear trend). This trend was also significant (P<0.001) when the number of doses of a gonadotropin-releasing hormone agonist received during the 24 months after diagnosis was examined (data not shown). The relative risk of any fracture was 1.45 (95 percent confidence interval, 1.36 to 1.56) among those receiving nine or more doses of gonadotropin-releasing hormone agonist in the first 12 months after diagnosis and 1.54 (95 percent confidence interval, 1.42 to 1.68) among those who underwent orchiectomy. For the relative risk of fracture resulting in hospitalization, the risk was 1.66 (95 percent confidence interval, 1.47 to 1.87) for nine or more doses of gonadotropin-releasing hormone agonist and 1.70 (95 percent confidence interval, 1.48 to 1.96) for orchiectomy.
With reference to the sites of fracture typically associated with osteoporosis (e.g., hip, spine, and forearm), the relative risk was 1.62 (95 percent confidence interval, 1.47 to 1.78) for nine or more doses of gonadotropin-releasing hormone agonist in the year after diagnosis and 1.63 (95 percent confidence interval, 1.45 to 1.82) for orchiectomy. Among patients with nonmetastatic disease (AJCC stage I, II, or III and a low-to-moderate grade of prostate cancer), the relative risk of any fracture was 1.37 (95 percent confidence interval, 1.20 to 1.57) for nine or more doses of gonadotropin-releasing hormone agonist. In the analyses limited to patients who received androgen deprivation as primary therapy (with patients who underwent radical prostatectomy or radiation excluded) or to patients who received androgen deprivation as adjuvant therapy (concomitantly with radical prostatectomy or radiation), the relative risks of any fracture were 1.44 (95 percent confidence interval, 1.33 to 1.56) and 1.53 (95 percent confidence interval, 1.32 to 1.78), respectively, among those receiving nine or more doses of gonadotropin-releasing hormone agonist.
Examination for Interaction
Interactions were tested on the basis of the Cox model presented in Table 3. There were no statistically significant interactions between cancer stage or race or ethnic group and androgen deprivation. There were significant interactions between scores on the comorbidity index and androgen deprivation (P=0.005), and between age and androgen deprivation (P=0.01) on the risk of fracture. The relative risk of any fracture at different doses of gonadotropin-releasing hormone agonist or with orchiectomy tended to decline with advancing age, although subjects 80 years of age or older who received nine or more doses of gonadotropin-releasing hormone agonist were still at an increased risk of subsequent fracture (relative risk, 1.32; 95 percent confidence interval, 1.18 to 1.48). The relative risk of fracture related to androgen-deprivation therapy decreased with an increasing score on the modified Charlson comorbidity index.18,19 For instance, the relative risk of fracture with nine or more doses of gonadotropin-releasing hormone agonist was 1.62 (95 percent confidence interval, 1.48 to 1.76) for a score of 0 on the comorbidity index, but it was 1.03 (95 percent confidence interval, 0.82 to 1.31) for a score of 3 or more on the comorbidity index. The full model for these interactions is presented in the Supplementary Appendix.
Numbers Needed to Harm
The number needed to harm for the occurrence of any fracture during the period 12 to 60 months after the diagnosis of prostate cancer was 28 (95 percent confidence interval, 26 to 31) for any use of a gonadotropin-releasing hormone agonist and 16 (95 percent confidence interval, 13 to 19) for orchiectomy. Because the relative risk of fracture varied according to the age of the subject and the total number of doses of gonadotropin-releasing hormone agonist received in the year after diagnosis, this relationship was expressed by calculating the number needed to harm according to age and number of doses (Table 4Table 4
Estimated Number Needed to Harm for the Occurrence of Any Fracture within 12 to 60 Months after Diagnosis, According to Age and Extent of Androgen Deprivation.). There was a pattern of lower numbers needed to harm with an increasing total number of doses of gonadotropin-releasing hormone agonist administered and with increasing age. For example, the number needed to harm was 74 (95 percent confidence interval, 50 to 146) among those 66 to 69 years of age who received one to four doses of a gonadotropin-releasing hormone agonist during the year after receiving the diagnosis of prostate cancer, whereas it was 12 (95 percent confidence interval, 11 to 13) among those 80 years of age or older who received nine or more doses during the same period.Discussion
We found that androgen-deprivation therapy is associated with an increase in the risk of fracture among older men with prostate cancer. The risk increases with the number of doses of a gonadotropin-releasing hormone agonist administered during the first year after diagnosis. This study provides an estimate of the risk of fracture that is attributable to androgen-deprivation therapy by including patients who were not treated with androgen deprivation and adjusting for confounding variables.
The hazard ratios we found were moderate but could nevertheless be clinically important, given the substantial underlying rate of fracture in our study population, which consisted of elderly men. Given an annual incidence of prostate cancer of more than 220,000, given that more than 40 percent of patients receive gonadotropin-releasing hormone agonists as an initial treatment,5,6 and given a number needed to harm of 28, approximately 3000 excess fractures per year would be attributable to the use of treatment with gonadotropin-releasing hormone agonists.
Several confounding factors may account for the apparent risk of fracture related to androgen deprivation. Older age and more advanced stages of cancer are associated with both androgen-deprivation treatment4 and fracture.29 In addition, patients who are about to undergo androgen-deprivation therapy tend already to have lower bone-mineral density.12,30 However, the association between androgen deprivation and fracture remained after extensive adjustment for known confounders and preexisting bone disease, and our results have biologic plausibility. Both orchiectomy and gonadotropin-releasing hormone agonists accelerate bone loss,29,31 and low bone-mineral density is strongly associated with an increased risk of fracture.32 Moreover, there was a significant dose–response relation between the number of doses of gonadotropin-releasing hormone agonists administered and the risk of fracture.
A limitation of the study was that we did not exclude from the analysis fractures that were related to bone metastases. However, only 7 to 16 percent of the fractures in prostate cancer are secondary to bone metastases.14,15 In addition, the risk of fracture associated with androgen-deprivation therapy was not reduced when the analysis was restricted to patients with early-stage cancer, who would be less likely to have bone metastases. Another limitation was that we restricted our analysis to the risk of fracture associated with the number of doses of a gonadotropin-releasing hormone agonist given in the first year after diagnosis. Longer periods of exposure to gonadotropin-releasing hormone agonists may be associated with a higher risk of fracture.33
One important implication of this study concerns the assessment of the risks and benefits of androgen-deprivation therapy. There was a dramatic increase in the use of such therapy during the 1990s4-6 (Table 1). The reasons for this increase may include demonstrated efficacy in patients with locally advanced cancer, the financial incentives to providers, and the urge, on the part of physicians and patients, to do something in the face of a rising PSA level. Our findings, along with those of smaller clinical series,13-15 underscore that such treatment is not benign. The risk of fracture and other toxic effects should therefore figure prominently in discussions between physician and patient with regard to the decision to initiate androgen-deprivation therapy, particularly in settings where its efficacy is uncertain. Most of the patients in whom androgen deprivation is used as the primary therapy have localized prostate cancer,4 and gonadotropin-releasing hormone agonists are commonly prescribed for patients with a rising PSA level after radical prostatectomy. Yet there is no evidence from clinical trials of a survival benefit for androgen-deprivation therapy in either of these settings.1
A second implication is that trials of interventions to lower the risk of fracture among patients with prostate cancer are needed. Parenterally administered bisphosphonates have been shown to prevent the loss of bone-mineral density after androgen-deprivation therapy for prostate cancer.34,35 Current recommendations are that men with prostate cancer who are being treated with androgen deprivation should have their bone-mineral density monitored and should commence bisphosphonate therapy if osteoporosis develops or a fracture occurs.16 Large prospective trials are required to assess the efficacy and the cost-effectiveness of bisphosphonate treatment to reduce the risk of fracture among men receiving androgen-deprivation therapy.
In conclusion, our study shows that androgen deprivation in the form of orchiectomy or treatment with gonadotropin-releasing hormone agonists is associated with an increased risk of fracture in patients with prostate cancer. This finding underscores the need for caution in the use of these therapies in settings without clear evidence of a benefit. Trials of therapies such as bisphosphonates to lower the risk of fracture are needed in patients for whom gonadotropin-releasing hormone agonists are clearly indicated.
Supported in part by grants (P50CA12385 and R24HS51161) from the Public Health Service.
We are indebted to the Applied Research Program, National Cancer Institute; to the Office of Research, Development, and Information, Centers for Medicare and Medicaid Services; to Information Management Services; and to the SEER Program for the creation of the SEER–Medicare database. The interpretation and reporting of the data are the sole responsibility of the authors.
Source Information
From the Departments of Internal Medicine (V.B.S., Y.-F.K., J.L.F., J.S.G.) and Preventive Medicine and Community Health (Y.-F.K., J.L.F., J.S.G.), and the Sealy Center on Aging (V.B.S., Y.-F.K., J.L.F., J.S.G.) — all at the University of Texas Medical Branch, Galveston.
Address reprint requests to Dr. Shahinian at the Department of Internal Medicine, University of Texas Medical Branch, John Sealy Annex, Rm. 4.200, 301 University Blvd., Galveston, TX 77555-0562, or at vbshahin@utmb.edu.
- References
References
1
Chodak GW ,Keane T ,Klotz L . Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002;60:201-208
CrossRef | Web of Science | Medline2
Huggins C ,Hodges CV . Studies on prostate cancer. I. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297
Web of Science3
Bolla M ,Collette L ,Blank L , et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-108
CrossRef | Web of Science | Medline4
Cooperberg MR ,Grossfeld GD ,Lubeck DP ,Carroll PR . National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-989
CrossRef | Web of Science | Medline5
Meng MV ,Grossfeld GD ,Sadetsky N ,Mehta SS ,Lubeck DP ,Carroll PR . Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 2002;60:Suppl 1:7-12
CrossRef | Web of Science | Medline6
Awodipe A ,Kuo Y ,Rajj M ,Shahinian V ,Freeman J ,Goodwin J . Survival outcome after adjuvant leuprolide therapy in elderly men with early prostate cancer. J Am Geriatr Soc 2004;52:Suppl 1:S162-S162 abstract.
CrossRef | Web of Science7
Harlan LC ,Potosky A ,Gilliland FD , et al. Factors associated with initial therapy for clinically localized prostate cancer: Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001;93:1864-1871
CrossRef | Web of Science | Medline8
Milbank AJ ,Dreicer R ,Klein EA . Hormonal therapy for prostate cancer: primum non nocere. Urology 2002;60:738-741
CrossRef | Web of Science | Medline9
Soloway MS . Timing of androgen deprivation for prostate cancer: benefits versus side effects -- a patient-physician dialogue. Urology 2002;60:735-737
CrossRef | Web of Science | Medline10
Oefelein MG ,Ricchiuti V ,Conrad W ,Resnick MI . Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-1007
CrossRef | Web of Science | Medline11
Mittan D ,Lee S ,Miller E ,Perez RC ,Basler JW ,Bruder JM . Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87:3656-3661
CrossRef | Web of Science | Medline12
Daniell HW ,Dunn SR ,Ferguson DW ,Lomas G ,Niazi Z ,Stratte PT . Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181-186
CrossRef | Web of Science | Medline13
Oefelein MG ,Ricchuiti V ,Conrad W , et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001;166:1724-1728
CrossRef | Web of Science | Medline14
Melton LJ III ,Alothman KI ,Khosla S ,Achenbach SJ ,Oberg AL ,Zincke H . Fracture risk following bilateral orchiectomy. J Urol 2003;169:1747-1750
CrossRef | Web of Science | Medline15
Townsend MF ,Sanders WH ,Northway RO ,Graham SD Jr . Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997;79:545-550
CrossRef | Web of Science | Medline16
Diamond TH ,Higano CS ,Smith MR ,Guise TA ,Singer FR . Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-899
CrossRef | Web of Science | Medline17
Warren JL ,Klabunde CN ,Schrag D ,Bach PB ,Riley GF . Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40:Suppl IV:3-18
Web of Science18
Charlson ME ,Pompei P ,Ales KL ,Mackenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383
CrossRef | Medline19
Klabunde CN ,Potosky AL ,Legler JM ,Warren JL . Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-1267
CrossRef | Web of Science | Medline20
Prostate cancer. In: Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for staging of cancer. 3rd ed. Philadelphia: Lippincott, 1988:177-9.
21
Prostate cancer. In: Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven,1997:219-22.
22
Prostate cancer. In: Greene FL, Page DL, Fleming ID, et al., eds. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002:310-1.
23
Fowler FJ Jr ,Collins MM ,Corkery EW ,Elliott DB ,Barry MJ . The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002;95:287-295
CrossRef | Web of Science | Medline24
Lamont EB ,Lauderdale DS ,Schilsky RL ,Christakis NA . Construct validity of Medicare chemotherapy claims: the case of 5FU. Med Care 2002;40:201-211
CrossRef | Web of Science | Medline25
Cooper GS ,Yuan Z ,Stange KC ,Dennis LK ,Amini SB ,Rimm AA . Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Med Care 2000;38:411-421
CrossRef | Web of Science | Medline26
Virnig BA ,Warren JL ,Cooper GS ,Klabunde CN ,Schussler N ,Freeman J . Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002;40:Suppl IV:49-54
Web of Science27
Du XL ,Freeman JL ,Goodwin JS . Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. J Clin Epidemiol 1999;52:463-470
CrossRef | Web of Science | Medline28
Ray WA ,Griffin MR ,Fought RL ,Adams ML . Identification of fractures from computerized Medicare files. J Clin Epidemiol 1992;45:703-714
CrossRef | Web of Science | Medline29
Smith MR . Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 2002;60:Suppl 1:79-86
CrossRef | Web of Science | Medline30
Wei JT ,Gross M ,Jaffe CA , et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999;54:607-611
CrossRef | Web of Science | Medline31
Ross RW ,Small EJ . Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002;167:1952-1956
CrossRef | Web of Science | Medline32
Cummings SR ,Black DM ,Nevitt MC , et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-75
CrossRef | Web of Science | Medline33
Morote J ,Martinez E ,Trilla E , et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 2003;44:661-665
CrossRef | Web of Science | Medline34
Smith MR ,McGovern FJ ,Zietman AL , et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-955
Full Text | Web of Science | Medline35
Smith MR ,Eastham J ,Gleason DM ,Shasha D ,Tchekmedyian S ,Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-2012
CrossRef | Web of Science | Medline
- Citing Articles (293)
Citing Articles
1
Joaquim Bellmunt, Gerhardt Attard, Amit Bahl, Hartwig Huland, Laurence Klotz, Deborah Kuban, Stéphane Oudard, William Watson. (2012) Advances in the management of high-risk localised and metastatic prostate cancer. BJU International 109, 8-13
CrossRef2
C. Hennequin, P. Mongiat-Artus, L. Quero, D. Pouessel, S. Culine. (2012) Les effets secondaires de l’hormonothérapie et leur gestion. Oncologie
CrossRef3
Pim J. van Leeuwen, Suzie J. Otto, Ries Kranse, Monique J. Roobol, Meelan Bul, Xiaoye Zhu, Harry de Koning, Fritz H. Schröder. (2012) Increased non-prostate cancer death risk in clinically diagnosed prostate cancer. BJU Internationalno-no
CrossRef4
Rebeca Reyes García, Esteban Jódar Gimeno, Antonia García Martín, Manuel Romero Muñoz, José Manuel Gómez Sáez, Inés Luque Fernández, Mariela Varsavsky, Sonsoles Guadalix Iglesias, Isidoro Cano Rodriguez, María Dolores Ballesteros Pomar, Alfonso Vidal Casariego, Pedro Rozas Moreno, María Cortés Berdonces, Diego Fernández García, Amparo Calleja Canelas, Mercedes Palma Moya, Guillermo Martínez Díaz-Guerra, José J. Jimenez Moleón, Manuel Muñoz Torres. (2012) Guías de práctica clínica para la evaluación y tratamiento de la osteoporosis asociada a enfermedades endocrinas y nutricionales. Endocrinología y Nutrición
CrossRef5
Janet E. Brown, Robert E. Coleman. (2012) Denosumab in patients with cancer—a surgical strike against the osteoclast. Nature Reviews Clinical Oncology
CrossRef6
Rowan G Casey, Niall M Corcoran, S Larry Goldenberg. (2012) Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian Journal of Andrology
CrossRef7
E K Watson, P W Rose, R D Neal, N Hulbert-Williams, P Donnelly, G Hubbard, J Elliott, C Campbell, D Weller, C Wilkinson. (2012) Personalised cancer follow-up: risk stratification, needs assessment or both?. British Journal of Cancer 106:1, 1-5
CrossRef8
B. Fall, K. Tengue, Y. Sow, A. Sarr, A. Thiam, S. Mohamed, B. Diao, P.A. Fall, A.K. Ndoye, M. Ba, B.A. Diagne. (2012) Place de la pulpectomie bilatérale dans la suppression androgénique pour cancer de la prostate. Progrès en Urologie
CrossRef9
Alicia K. Morgans, Michael L. Hancock, K. Gary Barnette, Mitchell S. Steiner, Ronald A. Morton, Matthew R. Smith. (2012) Racial Differences in Bone Mineral Density and Fractures in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. The Journal of Urology
CrossRef10
Giovanni Corona, Mauro Gacci, Elisabetta Baldi, Gianni Forti, Mario Maggi. 2011. Risk and Benefit of Androgen Deprivation Therapy in Prostate Cancer. , 55-71.
CrossRef11
Matthew R. Smith, S. Bruce Malkowicz, Michael K. Brawer, Michael L. Hancock, Ronald A. Morton, Mitchell S. Steiner. (2011) Toremifene Decreases Vertebral Fractures in Men Younger Than 80 Years Receiving Androgen Deprivation Therapy for Prostate Cancer. The Journal of Urology 186:6, 2239-2244
CrossRef12
N F Khan, D Mant, L Carpenter, D Forman, P W Rose. (2011) Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. British Journal of Cancer 105, S29-S37
CrossRef13
Murray Krahn, Karen E. Bremner, George Tomlinson, Jin Luo, Paul Ritvo, Gary Naglie, Shabbir M.H. Alibhai. (2011) Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?. BJU International 108:10, 1588-1596
CrossRef14
Peyman Hadji. (2011) Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease. Critical Reviews in Oncology/Hematology 80:2, 301-313
CrossRef15
Scott M. Gilbert, Yong-fang Kuo, Vahakn B. Shahinian. (2011) Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urologic Oncology: Seminars and Original Investigations 29:6, 647-653
CrossRef16
J. A. Kanis, G. Bianchi, J. P. Bilezikian, J.-M. Kaufman, S. Khosla, E. Orwoll, E. Seeman. (2011) Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporosis International 22:11, 2789-2798
CrossRef17
Karen Tipples, Anne Robinson. (2011) Optimal Management of Cancer Treatment-Induced Bone Loss. Drugs & Aging 28:11, 867-883
CrossRef18
Padraig Warde, Malcolm Mason, Keyue Ding, Peter Kirkbride, Michael Brundage, Richard Cowan, Mary Gospodarowicz, Karen Sanders, Edmund Kostashuk, Greg Swanson, Jim Barber, Andrea Hiltz, Mahesh KB Parmar, Jinka Sathya, John Anderson, Charles Hayter, John Hetherington, Matthew R Sydes, Wendy Parulekar. (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet
CrossRef19
Jennifer L. Beebe-Dimmer, Karynsa Cetin, Vahakn Shahinian, Hal Morgenstern, Cecilia Yee, Kendra L. Schwartz, John Acquavella. (2011) Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef20
Gregory A Clines, Khalid S Mohammad, Jessica M Grunda, Katrina L Clines, Maria Niewolna, C Ryan McKenna, Christopher R McKibbin, Masashi Yanagisawa, Larry J Suva, John M Chirgwin, Theresa A Guise. (2011) Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. Journal of Bone and Mineral Research 26:10, 2523-2536
CrossRef21
Yutaka Fujisue, Haruhito Azuma, Teruo Inamoto, Kazumasa Komura, Piyush K. Agarwal, Hiroshi Masuda, Toshikazu Watsuji, Yoji Katsuoaka. (2011) Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer. World Journal of Urology 29:5, 689-694
CrossRef22
Natalia Sadetsky, Kirsten Greene, Matthew R. Cooperberg, Alan Hubbard, Peter R. Carroll, William Satariano. (2011) Impact of androgen deprivation on physical well-being in patients with prostate cancer. Cancer 117:19, 4406-4413
CrossRef23
P. Claudon, R. Spie, M. Bats, F. Saint, J. Petit. (2011) Efficacité à moyen terme du traitement de l’incontinence urinaire d’effort masculine par bandelette prothétique sous-urétrale à ancrage osseux type InVance™. Progrès en Urologie 21:9, 625-630
CrossRef24
Sean P. Elliott, Stephanie L. Jarosek, Shaheen R. Alanee, Badrinath R. Konety, Kathryn E. Dusenbery, Beth A. Virnig. (2011) Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture. Cancer 117:19, 4557-4565
CrossRef25
Mathis Grossmann, Jeffrey D. Zajac. (2011) Management of Side Effects of Androgen Deprivation Therapy. Endocrinology & Metabolism Clinics of North America 40:3, 655-671
CrossRef26
Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, Pär Stattin, Jan Adolfsson. (2011) Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden. European Urology
CrossRef27
Shiu-Dong Chung, Yi-Kuang Chen, Fang-Jen Wu, Herng-Ching Lin. (2011) Hormone therapy for prostate cancer and the risk of stroke: a 5-year follow-up study. BJU Internationalno-no
CrossRef28
René Maltais, Michelle-Audrey Fournier, Donald Poirier. (2011) Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorganic & Medicinal Chemistry 19:15, 4652-4668
CrossRef29
R. Mistry, D. Hughes, V. Wadhwa, N. Parr. (2011) Lateral Spine Radiographs Before Androgen Deprivation Treatment Detect a High Incidence of Undiagnosed Vertebral Fragility Fractures in Men With Advanced Prostate Cancer. The Journal of Urology 186:2, 474-481
CrossRef30
Philip J. Saylor, Ronald A. Morton, Michael L. Hancock, K. Gary Barnette, Mitchell S. Steiner, Matthew R. Smith. (2011) Factors Associated With Vertebral Fractures in Men Treated With Androgen Deprivation Therapy for Prostate Cancer. The Journal of Urology 186:2, 482-486
CrossRef31
Vincenzo Pagliarulo, Sergio Bracarda, Mario A. Eisenberger, Nicolas Mottet, Fritz H. Schröder, Cora N. Sternberg, Urs E. Studer. (2011) Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer. European Urology
CrossRef32
L Joseph Melton, Michael M Lieber, Elizabeth J Atkinson, Sara J Achenbach, Horst Zincke, Terry M Therneau, Sundeep Khosla. (2011) Fracture risk in men with prostate cancer: A population-based study. Journal of Bone and Mineral Research 26:8, 1808-1815
CrossRef33
D. J. Betteridge. (2011) Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Diabetic Medicine 28:7, 759-771
CrossRef34
Vivek K. Wadhwa, Robin Weston, Nigel J. Parr. (2011) Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer. BJU International 107:12, 1923-1929
CrossRef35
Brian J. Gates, Shyamal Das. (2011) Management of osteoporosis in elderly men. Maturitas 69:2, 113-119
CrossRef36
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Smith, Matthew R., Zietman, Anthony L., Finkelstein, Joel S., Wu, Chin-Lee, . (2011) Case 16-2011. New England Journal of Medicine 364:21, 2044-2051
Full Text37
Angela S. Alberga, Roanne J. Segal, Robert D. Reid, Chris G. Scott, Ronald J. Sigal, Farah Khandwala, James Jaffey, George A. Wells, Glen P. Kenny. (2011) Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer. Supportive Care in Cancer
CrossRef38
T. Lebret, A. Méjean, N. Houédé. (2011) Physiopathologie et nouvelles stratégies thérapeutiques dans la prise en charge des métastases osseuses du cancer de la prostate. Progrès en Urologie 21:5, 301-307
CrossRef39
Ari VanderWalde, Arti Hurria. (2011) Aging and osteoporosis in breast and prostate cancer. CA: A Cancer Journal for Clinicians 61:3, 139-156
CrossRef40
James W Denham, Allison Steigler, David S Lamb, David Joseph, Sandra Turner, John Matthews, Chris Atkinson, John North, David Christie, Nigel A Spry, Keen-Hun Tai, Chris Wynne, Catherine D'Este. (2011) Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. The Lancet Oncology 12:5, 451-459
CrossRef41
Paul de Souza, Fred Saad. (2011) Bone health in prostate cancer. Expert Review of Endocrinology & Metabolism 6:3, 317-321
CrossRef42
Jarad M. Martin, Stephane Supiot, Dominik R. Berthold. (2011) Pharmacotherapeutic Management of Locally Advanced Prostate Cancer. Drugs 71:8, 1019-1041
CrossRef43
Minoru Kobayashi, Akinori Nukui, Kazumi Suzuki, Shinsuke Kurokawa, Tatsuo Morita. (2011) Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience. International Journal of Clinical Oncology
CrossRef44
Kathryn Bylow, Joshua Hemmerich, Supriya G. Mohile, Walter M. Stadler, Saleha Sajid, William Dale. (2011) Obese Frailty, Physical Performance Deficits, and Falls in Older Men with Biochemical Recurrence of Prostate Cancer on Androgen Deprivation Therapy: A Case-control Study. Urology 77:4, 934-940
CrossRef45
Françoise Debiais. (2011) Inhibiteurs de l’aromatase, analogues de la LH-RH et ostéoporose. Revue du Rhumatisme Monographies 78:2, 81-87
CrossRef46
C. J. D. Pitts, A. E. Kearns. (2011) Update on Medications With Adverse Skeletal Effects. Mayo Clinic Proceedings 86:4, 338-343
CrossRef47
Mathis Grossmann, Jeffrey D. Zajac. (2011) Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?. Clinical Endocrinology 74:3, 289-293
CrossRef48
Robert A. Adler. (2011) Osteoporosis in Men: What has Changed?. Current Osteoporosis Reports 9:1, 31-35
CrossRef49
Jean-Baptiste Lattouf, Hicham Fadlallah, Fred Saad. (2011) Androgen Deprivation and Bone. Current Osteoporosis Reports 9:1, 20-24
CrossRef50
Jennifer Beebe-Dimmer, Hal Morgenstern, Karynsa Cetin, Cecilia Yee, Monina Bartoces, Vahakn Shahinian, Jon Fryzek, John Acquavella, Kendra L. Schwartz. (2011) Androgen Deprivation Therapy and Cataract Incidence Among Elderly Prostate Cancer Patients in the United States. Annals of Epidemiology 21:3, 156-163
CrossRef51
Bente Thoft Jensen, Pascale Dielenseger, Lawrence Drudge-Coates, Karen Flynn, Susanne Hieronymi, H.A.M (Erik) van Muilekom, Ronny Pieters, Lisbeth Bjerregaard Voss. (2011) Taking the lead – Sharing best practice in intravenous bisphosphonate use in urological cancers. European Journal of Oncology Nursing
CrossRef52
(2011) Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine 364:6, 579-580
Full Text53
Robert A. Adler. (2011) Management of osteoporosis in men on androgen deprivation therapy. Maturitas 68:2, 143-147
CrossRef54
Tilman Todenhoefer, Georgios Gakis, David Schilling, Gerhard Feil, Christian Schwentner, Arnulf Stenzl. (2011) Diagnosis and treatment of prostate cancer-related bone disease. Clinical Investigation 1:2, 265-283
CrossRef55
Richard J. Lee, Philip J. Saylor, Matthew R. Smith. (2011) Treatment and prevention of bone complications from prostate cancer. Bone 48:1, 88-95
CrossRef56
Vahakn B. Shahinian. (2011) Androgen deprivation for prostate cancer. Cancern/a-n/a
CrossRef57
Alicia K. Morgans, Matthew R. Smith. (2011) RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis. Journal of Osteoporosis 2011, 1-6
CrossRef58
E. Michael Lewiecki, John P. Bilezikian, Sundeep Khosla, Robert Marcus, Michael R. McClung, Paul D. Miller, Nelson B. Watts, Michael Maricic. (2011) Osteoporosis Update From the 2010 Santa Fe Bone Symposium. Journal of Clinical Densitometry 14:1, 1-21
CrossRef59
Vahakn B. Shahinian. (2011) Prostate cancer: Reducing fracture risk in men on androgen deprivation therapy. Nature Reviews Urology 8:1, 9-10
CrossRef60
J. Morote, J. Planas. (2011) Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation. Actas Urológicas Españolas (English Edition) 35:4, 232-239
CrossRef61
Naohiro Fujimoto, Tatsuhiko Kubo, Hideo Shinsaka, Masahiro Matsumoto, Shohei Shimajiri, Tetsuro Matsumoto. (2011) Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer. BMC Urology 11:1, 7
CrossRef62
Matthew R Smith, Fred Saad, Blair Egerdie, Paul Sieber, Teuvo LJ Tammela, Benjamin Z Leder, Chunlei Ke, Carsten Goessl. (2011) Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. Journal of Bone and Mineral Researchn/a-n/a
CrossRef63
Daniel A Galvao, Dennis R Taaffe, Prue Cormie, Nigel Spry, Suzanne K Chambers, Carolyn Peddle-McIntyre, Michael Baker, James Denham, David Joseph, Geoff Groom, Robert U Newton. (2011) Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial. BMC Cancer 11:1, 517
CrossRef64
S. P. Elliott, S. L. Jarosek, T. J. Wilt, B. A. Virnig. (2010) Reduction in Physician Reimbursement and Use of Hormone Therapy in Prostate Cancer. JNCI Journal of the National Cancer Institute 102:24, 1826-1834
CrossRef65
N. L. Keating. (2010) Medicare Reimbursement and Prescribing Hormone Therapy for Prostate Cancer. JNCI Journal of the National Cancer Institute 102:24, 1814-1815
CrossRef66
Richard J. Lee, Philip J. Saylor, Matthew R. Smith. (2010) Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer. Clinical Genitourinary Cancer 8:1, 29-36
CrossRef67
AJ Hayden, JM Martin, AB Kneebone, M Lehman, KL Wiltshire, M Skala, D Christie, P Vial, R McDowall, K-H Tai. (2010) Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma. Journal of Medical Imaging and Radiation Oncology 54:6, 513-525
CrossRef68
Fred Saad, James A. Eastham, Matthew R. Smith. (2010) Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urologic Oncology: Seminars and Original Investigations
CrossRef69
S. Gillessen, A. Templeton, G. Marra, Y.-F. Kuo, E. Valtorta, V. B. Shahinian. (2010) Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. JNCI Journal of the National Cancer Institute 102:23, 1760-1770
CrossRef70
Shahinian, Vahakn B., Kuo, Yong-Fang, Gilbert, Scott M., . (2010) Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine 363:19, 1822-1832
Full Text71
Pamela Taxel, Robert Dowsett, Lee Richter, Pamela Fall, Alison Klepinger, Peter Albertsen. (2010) Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU International 106:10, 1473-1476
CrossRef72
Michel Bolla, Geertjan Van Tienhoven, Padraig Warde, Jean Bernard Dubois, René-Olivier Mirimanoff, Guy Storme, Jacques Bernier, Abraham Kuten, Cora Sternberg, Ignace Billiet, José Lopez Torecilla, Raphael Pfeffer, Carmel Lino Cutajar, Theodore Van der Kwast, Laurence Collette. (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. The Lancet Oncology 11:11, 1066-1073
CrossRef73
J.- J. Body. (2010) Prevention and treatment of side-effects of systemic treatment: bone loss. Annals of Oncology 21:Supplement 7, vii180-vii185
CrossRef74
Bertrand Tombal. (2010) Prostate Cancer Management: What Does the Future Hold?. European Urology Supplements 9:8, 706-714
CrossRef75
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A. Schalken, Francesco Montorsi, Piotr L. Chlosta, Axel Heidenreich. (2010) Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. European Urology Supplements 9:7, 675-691
CrossRef76
Matthew R. Smith, Ronald A. Morton, K. Gary Barnette, Paul R. Sieber, S. Bruce Malkowicz, Domingo Rodriguez, Michael L. Hancock, Mitchell S. Steiner. (2010) Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. The Journal of Urology 184:4, 1316-1321
CrossRef77
James H. Pickar, Tanya MacNeil, Kathleen Ohleth. (2010) SERMs: Progress and future perspectives. Maturitas 67:2, 129-138
CrossRef78
Kerri M. Winters-Stone, Anna Schwartz, Lillian M. Nail. (2010) A review of exercise interventions to improve bone health in adult cancer survivors. Journal of Cancer Survivorship 4:3, 187-201
CrossRef79
Howard S Kim, Stephen J Freedland. (2010) Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Current Opinion in Supportive and Palliative Care 4:3, 147-152
CrossRef80
Shabbir M.H. Alibhai, Minh Duong-Hua, Angela M. Cheung, Rinku Sutradhar, Padraig Warde, Neil E. Fleshner, Lawrence Paszat. (2010) Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men. The Journal of Urology 184:3, 918-924
CrossRef81
Fred Saad, Allan Lipton. (2010) Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. Current Opinion in Supportive and Palliative Care 4:3, 127-134
CrossRef82
René Rizzoli, Uma Yasothan, Peter Kirkpatrick. (2010) Denosumab. Nature Reviews Drug Discovery 9:8, 591-592
CrossRef83
SRC McCracken, GC Durkan, RS Pickard, CN Robson. (2010) Diagnosis and management of prostate cancer in the older man. Reviews in Clinical Gerontology 20:03, 193-204
CrossRef84
Mary Beth O’Connell, Laura M Borgelt, Susan K Bowles, Sheryl F Vondracek. (2010) Drug-induced osteoporosis in the older adult. Aging Health 6:4, 501-518
CrossRef85
Jean-Pierre Droz, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michael W. Kattan, Silvio Monfardini, Judd W. Moul, Arash Naeim, Hendrik van Poppel, Fred Saad, Cora N. Sternberg. (2010) Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU International 106:4, 462-469
CrossRef86
Vinod E Nambudiri, Nancy L Keating. (2010) Metabolic and cardiovascular risks of androgen-deprivation therapy for prostate cancer. Expert Review of Endocrinology & Metabolism 5:4, 531-537
CrossRef87
Şefik İğdem, Gül Alço, Tülay Ercan, Metin Barlan, Kürşat Ganiyusufoğlu, Bülent Ünalan, Sedat Turkan, Sait Okkan. (2010) Insufficiency Fractures After Pelvic Radiotherapy in Patients With Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 77:3, 818-823
CrossRef88
Christopher R. King, Peter G. Maxim, Annie Hsu, Daniel S. Kapp. (2010) Incidental Testicular Irradiation From Prostate IMRT: It All Adds Up. International Journal of Radiation Oncology*Biology*Physics 77:2, 484-489
CrossRef89
Farhana Haseen, Liam J. Murray, Chris R. Cardwell, Joe M. O’Sullivan, Marie M. Cantwell. (2010) The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. Journal of Cancer Survivorship 4:2, 128-139
CrossRef90
Robert A. Adler. (2010) Osteoporosis, Androgen Levels and Urological Care. The Journal of Urology 183:6, 2122-2123
CrossRef91
J. Lorthiois, V. Skowronski, M. Fleury, J.-B. Gauvain. (2010) Comment identifier les sujets âgés à risque de fracture éligibles à un traitement ?. Les cahiers de l'année gérontologique 2:2, 71-79
CrossRef92
Allan Lipton. (2010) Bone Continuum of Cancer. American Journal of Clinical Oncology 33:Supplement, S1-S7
CrossRef93
Jean-Pierre Droz, Catherine Terret. (2010) Assessing older prostate cancer patients for chemotherapy: recommendations from the International Society of Geriatric Oncology. Aging Health 6:3, 365-369
CrossRef94
Jason E Faris, Matthew R Smith. (2010) Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity 17:3, 240-246
CrossRef95
Shabbir Hussain, Henriette Breunis, Narhari Timilshina, Shabbir M.H. Alibhai. (2010) Falls in men on androgen deprivation therapy for prostate cancer. Journal of Geriatric Oncology 1:1, 32-39
CrossRef96
Naoto Kamiya, Hiroyoshi Suzuki, Masashi Yano, Takumi Endo, Makoto Takano, Atsuhi Komaru, Koji Kawamura, Nobuyuki Sekita, Takashi Imamoto, Tomohiko Ichikawa. (2010) Implications of Serum Bone Turnover Markers in Prostate Cancer Patients With Bone Metastasis. Urology 75:6, 1446-1451
CrossRef97
Philip J. Saylor, Donald S. Kaufman, M. Dror Michaelson, Richard J. Lee, Matthew R. Smith. (2010) Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer. The Journal of Urology 183:6, 2200-2205
CrossRef98
Steven C. Campbell, Nirmala Bhoopalam, Thomas E. Moritz, Mona Pandya, Padmini Iyer, Peter VanVeldhuizen, Nancy K. Ellis, Lizy Thottapurathu, Harinder Garewal, Stuart R. Warren, Nicholas Friedman, Domenic J. Reda. (2010) The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis. Urology 75:5, 1138-1143
CrossRef99
Takeshi Yuasa, Shinya Maita, Norihiko Tsuchiya, Zhiyong Ma, Shintaro Narita, Yohei Horikawa, Shinya Yamamoto, Junji Yonese, Iwao Fukui, Shunji Takahashi, Kiyohiko Hatake, Tomonori Habuchi. (2010) Relationship Between Bone Mineral Density and Androgen-deprivation Therapy in Japanese Prostate Cancer Patients. Urology 75:5, 1131-1137
CrossRef100
Alvan J. Pope, Paul D. Abel. (2010) Androgen deprivation therapy for prostate cancer and its complications. Trends in Urology, Gynaecology & Sexual Health 15:3, 32-37
CrossRef101
Jean-Baptiste Lattouf, Fred Saad. (2010) Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Current Opinion in Urology 20:3, 247-252
CrossRef102
Derek R. Wilke, Murray Krahn, George Tomlinson, Andrea Bezjak, Robert Rutledge, Padraig Warde. (2010) Sex or survival. Cancer 116:8, 1909-1917
CrossRef103
Christian Boukaram, Jean-Michel Hannoun-Levi. (2010) Management of prostate cancer recurrence after definitive radiation therapy. Cancer Treatment Reviews 36:2, 91-100
CrossRef104
Janet E. Brown, Jennifer M. Sherriff, Nicholas D. James. (2010) OSTEOPOROSIS IN PATIENTS WITH PROSTATE CANCER ON LONG-TERM ANDROGEN DEPRIVATION THERAPY: AN INCREASING, BUT UNDER-RECOGNIZED PROBLEM. BJU International 105:8, 1042-1043
CrossRef105
R. A. Adler, F. W. Hastings, V. I. Petkov. (2010) Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX™. Osteoporosis International 21:4, 647-653
CrossRef106
Vivek K. Wadhwa, Robin Weston, Nigel J. Parr. (2010) Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. BJU International 105:8, 1082-1088
CrossRef107
Cynthia Abarado, Suzanne M. Mahon. (2010) Androgen-Deprivation Bone Loss in Patients With Prostate Cancer. Clinical Journal of Oncology Nursing 14:2, 191-198
CrossRef108
P J Saylor, M R Smith. (2010) Bone health and prostate cancer. Prostate Cancer and Prostatic Diseases 13:1, 20-27
CrossRef109
Ann E. Kearns, Donald W. Northfelt, Amylou C. Dueck, Pamela J. Atherton, Shaker R. Dakhil, Kendrith M. Rowland, Jyotsna Fuloria, Patrick J. Flynn, Todor Dentchev, Charles L. Loprinzi. (2010) Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Supportive Care in Cancer 18:3, 321-328
CrossRef110
N. L. Keating, A. J. O'Malley, S. J. Freedland, M. R. Smith. (2010) Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer. JNCI Journal of the National Cancer Institute 102:1, 39-46
CrossRef111
Seth A. Rosenthal, Howard M. Sandler. (2010) Treatment strategies for high-risk locally advanced prostate cancer. Nature Reviews Urology 7:1, 31-38
CrossRef112
Jean-Pierre Droz, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michael W. Kattan, Silvio Monfardini, Judd W. Moul, Arash Naeim, Hendrik van Poppel, Fred Saad, Cora N. Sternberg. (2010) Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Critical Reviews in Oncology/Hematology 73:1, 68-91
CrossRef113
Kendall F. Moseley, Suzanne M. Jan de Beur. 2010. Osteoporosis in Men and Women. , 716-736.
CrossRef114
B LEDER. 2010. Androgens and the Skeleton – Humans. , 319-334.
CrossRef115
C MEIER. 2010. Testicular Dysfunction. , 423-434.
CrossRef116
E ORWOLL. 2010. Overall Approach to the Evaluation and Treatment of Osteoporosis in Men. , 589-601.
CrossRef117
Jacques Planas, Enrique Trilla, Carles Ravent
s, Lluis Cecchini, Anna Orsola, Carles Salvador, Jose Placer, Gloria Encabo, Juan Morote. (2009) Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU International 104:11, 1637-1640
CrossRef118
S J Freedland, J Eastham, N Shore. (2009) Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer and Prostatic Diseases 12:4, 333-338
CrossRef119
Neil Binkley. (2009) A perspective on male osteoporosis. Best Practice & Research Clinical Rheumatology 23:6, 755-768
CrossRef120
Eitan Amir, Ian F. Tannock. (2009) Prostate cancer: Androgen deprivation therapy and bone loss. Nature Reviews Urology 6:12, 642-644
CrossRef121
Matthew R. Smith, Fred Saad, Blair Egerdie, Maciej Szwedowski, Teuvo L.J. Tammela, Chunlei Ke, Benjamin Z. Leder, Carsten Goessl. (2009) Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. The Journal of Urology 182:6, 2670-2676
CrossRef122
Fred Saad, Per-Anders Abrahamsson, Kurt Miller. (2009) Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU International 104:11, 1573-1579
CrossRef123
S. Bruce Malkowicz. (2009) What Should Urologists Know About Osteoporosis?. The Journal of Urology 182:6, 2557-2558
CrossRef124
C. Kok, P.N. Sambrook. (2009) Secondary osteoporosis in patients with an osteoporotic fracture. Best Practice & Research Clinical Rheumatology 23:6, 769-779
CrossRef125
Nirmala Bhoopalam, Steven C. Campbell, Thomas Moritz, William R. Broderick, Padmini Iyer, Anthony G. Arcenas, Peter J. Van Veldhuizen, Nicholas Friedman, Domenic Reda, Stuart Warren, Harinder Garewal. (2009) Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy. The Journal of Urology 182:5, 2257-2264
CrossRef126
Hans Heinzer, Thomas Steuber. (2009) Prostate cancer in the elderly. Urologic Oncology: Seminars and Original Investigations 27:6, 668-672
CrossRef127
Matthew R. Smith. (2009) RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer. European Urology Supplements 8:11, 834-838
CrossRef128
Philip J. Saylor, Nancy L. Keating, Matthew R. Smith. (2009) Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy. Journal of General Internal Medicine 24:S2, 389-394
CrossRef129
Arnulf Stenzl. (2009) RANK Ligand: A Key Role in Cancer-Induced Bone Destruction?. European Urology Supplements 8:11, 823-828
CrossRef130
Matthew R. Smith, Gordon A. Brown, Fred Saad. (2009) New opportunities in the management of prostate cancer–related bone complications. Urologic Oncology: Seminars and Original Investigations 27:6, S1-S20
CrossRef131
Xiaodong Li, Michael S. Ominsky, Marina Stolina, Kelly S. Warmington, Zhaopo Geng, Qing-Tian Niu, Frank J. Asuncion, Hong-Lin Tan, Mario Grisanti, Denise Dwyer, Steven Adamu, Hua Zhu Ke, W. Scott Simonet, Paul J. Kostenuik. (2009) Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 45:4, 669-676
CrossRef132
Yu-Ning Wong, Stephen J. Freedland, Brian Egleston, Neha Vapiwala, Robert Uzzo, Katrina Armstrong. (2009) The Role of Primary Androgen Deprivation Therapy in Localized Prostate Cancer. European Urology 56:4, 609-616
CrossRef133
Henk G. van der Poel. (2009) Chemical Castration and Survival in Low-risk Prostate Cancer. European Urology 56:4, 617-618
CrossRef134
Cristina Falci, Elisabetta Morello, Jean Pierre Droz. (2009) Treatment of prostate cancer in unfit senior adult patients. Cancer Treatment Reviews 35:6, 522-527
CrossRef135
Nigel A. Spry, Daniel A. Galvão, Robert Davies, Shane La Bianca, David Joseph, Andrew Davidson, Richard Prince. (2009) Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU International 104:6, 806-812
CrossRef136
D A Galvão, D R Taaffe, N Spry, D Joseph, R U Newton. (2009) Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Prostate Cancer and Prostatic Diseases 12:3, 233-240
CrossRef137
N. Rolfes, G. Lümmen. (2009) Der Stellenwert von Bisphosphonaten in der Therapie des Prostatakarzinoms. Der Urologe 48:9, 990-996
CrossRef138
Vivek K. Wadhwa, Robin Weston, Rahul Mistry, Nigel J. Parr. (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU International 104:6, 800-805
CrossRef139
Kurt Miller, Arnulf Stenzl, Bertrand Tombal. (2009) Advances in the Therapy of Prostate Cancer–Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways. European Urology Supplements 8:9, 747-752
CrossRef140
Smith, Matthew R., Egerdie, Blair, Toriz, Narciso Hernández, Feldman, Robert, Tammela, Teuvo L.J., Saad, Fred, Heracek, Jiri, Szwedowski, Maciej, Ke, Chunlei, Kupic, Amy, Leder, Benjamin Z., Goessl, Carsten, . (2009) Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine 361:8, 745-755
Full Text141
Liesbeth Vandenput, Claes Ohlsson. (2009) Estrogens as regulators of bone health in men. Nature Reviews Endocrinology 5:8, 437-443
CrossRef142
Takefumi Satoh, Masaki Kimura, Kazumasa Matsumoto, Ken-ichi Tabata, Hiroshi Okusa, Hideharu Bessho, Masatsugu Iwamura, Hiromichi Ishiyama, Kazushige Hayakawa, Shiro Baba. (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 115:15, 3468-3474
CrossRef143
Lindsay S. Van Tongeren, Graeme G. Duncan, David L. Kendler, Howard Pai. (2009) Implementation of Osteoporosis Screening Guidelines in Prostate Cancer Patients on Androgen Ablation. Journal of Clinical Densitometry 12:3, 287-291
CrossRef144
Lodovico Balducci. (2009) Supportive care in elderly cancer patients. Current Opinion in Oncology 21:4, 310-317
CrossRef145
Bolla, Michel, de Reijke, Theodorus M., Van Tienhoven, Geertjan, Van den Bergh, Alphonsus C.M., Oddens, Jorg, Poortmans, Philip M.P., Gez, Eliahu, Kil, Paul, Akdas, Atif, Soete, Guy, Kariakine, Oleg, van der Steen-Banasik, Elsbietha M., Musat, Elena, Piérart, Marianne, Mauer, Murielle E., Collette, Laurence, . (2009) Duration of Androgen Suppression in the Treatment of Prostate Cancer. New England Journal of Medicine 360:24, 2516-2527
Full Text146
Kouji Izumi, Atsushi Mizokami, Kazuhiro Sugimoto, Kazutaka Narimoto, Sotaro Miwa, Yuji Maeda, Yoshifumi Kadono, Mitsuhiro Takashima, Eitetsu Koh, Mikio Namiki. (2009) Risedronate Recovers Bone Loss in Patients With Prostate Cancer Undergoing Androgen-deprivation Therapy. Urology 73:6, 1342-1346
CrossRef147
Tomoko Tagawa, Arti Hurria, Joanne Mortimer. (2009) Bone health maintenance in survivors of breast and prostate cancer. Aging Health 5:3, 301-311
CrossRef148
Charles J. Stava, Camilo Jimenez, Mimi I. Hu, Rena Vassilopoulou-Sellin. (2009) Skeletal sequelae of cancer and cancer treatment. Journal of Cancer Survivorship 3:2, 75-88
CrossRef149
Elisabetta Morello, Geremia Giordano, Cristina Falci, Silvio Monfardini. (2009) Rehabilitation in older cancer patients. Aging Health 5:3, 369-384
CrossRef150
Vivek K. Wadhwa, Nigel J. Parr. (2009) Peripheral or Axial Bone Density Measurements to Identify Osteoporosis in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy?. Urology 73:6, 1347-1351
CrossRef151
Supriya G. Mohile, Karen Mustian, Kathryn Bylow, William Hall, William Dale. (2009) Management of complications of androgen deprivation therapy in the older man. Critical Reviews in Oncology/Hematology 70:3, 235-255
CrossRef152
Lockwood G. Taylor, Steven E. Canfield, Xianglin L. Du. (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115:11, 2388-2399
CrossRef153
Brian L. Egleston, Yu-Ning Wong. (2009) Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data. Statistics in Medicine 28:10, 1498-1511
CrossRef154
Bhoomi Mehrotra. (2009) Bisphosphonates—Role in Cancer Therapies. Journal of Oral and Maxillofacial Surgery 67:5, 19-26
CrossRef155
Takamitsu Inoue, Takehiko Segawa, Tomomi Kamba, Koji Yoshimura, Eijiro Nakamura, Hiroyuki Nishiyama, Noriyuki Ito, Toshiyuki Kamoto, Tomonori Habuchi, Osamu Ogawa. (2009) Prevalence of Skeletal Complications and Their Impact on Survival of Hormone Refractory Prostate Cancer Patients in Japan. Urology 73:5, 1104-1109
CrossRef156
Anita Schwandt, Jorge A Garcia. (2009) Complications of androgen deprivation therapy in prostate cancer. Current Opinion in Urology 19:3, 322-326
CrossRef157
Paul Hoffmann, Claude Schulman. (2009) COMPLICATIONS OF ANDROGEN-DEPRIVATION THERAPY IN PROSTATE CANCER: THE OTHER SIDE OF THE COIN. BJU International 103:8, 1020-1023
CrossRef158
A. Papaioannou, C. C. Kennedy, A. Cranney, G. Hawker, J. P. Brown, S. M. Kaiser, W. D. Leslie, C. J. M. O’Brien, A. M. Sawka, A. Khan, K. Siminoski, G. Tarulli, D. Webster, J. McGowan, J. D. Adachi. (2009) Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporosis International 20:4, 507-518
CrossRef159
B. Abrahamsen, K. Brixen. (2009) Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk. Osteoporosis International 20:4, 585-597
CrossRef160
Abbas H. Panju, Henriette Breunis, Angela M. Cheung, Marc Leach, Neil Fleshner, Padraig Warde, Sarah Duff-Canning, Murray Krahn, Gary Naglie, Ian Tannock, George Tomlinson, Shabbir M.H. Alibhai. (2009) Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU International 103:6, 753-757
CrossRef161
Karine Briot, Bernard Cortet, Florence Trémollières, Bruno Sutter, Thierry Thomas, Christian Roux, Maurice Audran. (2009) Male osteoporosis: Diagnosis and fracture risk evaluation. Joint Bone Spine 76:2, 129-133
CrossRef162
Leyla H. Alparslan, Barbara N. Weissman. 2009. Imaging Findings of Drug-Related Musculoskeletal Disorders. , 264-279.
CrossRef163
Laurent Qu
CrossRef164
Etsuko Isahaya, Noboru Hara, Tsutomu Nishiyama, Tatsuhiko Hoshii, Itsuhiro Takizawa, Kota Takahashi. (2009) Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis. The Prostaten/a-n/a
CrossRef165
Hendrik Isbarn, Laurent Boccon-Gibod, Peter R. Carroll, Francesco Montorsi, Claude Schulman, Matthew R. Smith, Cora N. Sternberg, Urs E. Studer. (2009) Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks. European Urology 55:1, 62-75
CrossRef166
K. Briot, C. Roux. (2009) Perte osseuse liée aux hormonomodulateurs. Oncologie 11:1, 28-32
CrossRef167
Michael G. Oefelein. (2008) Androgen suppression therapy and prostate cancer. Cancer 113:12, 3275-3278
CrossRef168
Payam Hakimian, Michael Blute, James Kashanian, Sherman Chan, David Silver, Ridwan Shabsigh. (2008) Metabolic and cardiovascular effects of androgen deprivation therapy. BJU International 102:11, 1509-1514
CrossRef169
Supriya G. Mohile, Mark Lachs, William Dale. (2008) Management of Prostate Cancer in the Older Man. Seminars in Oncology 35:6, 597-617
CrossRef170
Marc Zerbib, Michael J. Zelefsky, Celestia S. Higano, Peter R. Carroll. (2008) Conventional Treatments of Localized Prostate Cancer. Urology 72:6, S25-S35
CrossRef171
Thomas W Flaig, L Michael Glodé. (2008) Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opinion on Pharmacotherapy 9:16, 2829-2841
CrossRef172
K. Miller, M. Lein, M. Schostak, M. Schrader. (2008) Adjuvante und neoadjuvante medikamentöse Therapie beim Prostatakarzinom. Der Urologe 47:11, 1460-1464
CrossRef173
P. Richaud. (2008) Hormonothérapie adjuvante à la radiothérapie. Oncologie 10:11, 641-647
CrossRef174
Jason A. Efstathiou, Kyounghwa Bae, William U. Shipley, Gerald E. Hanks, Miljenko V. Pilepich, Howard M. Sandler, Matthew R. Smith. (2008) Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. European Urology 54:4, 816-824
CrossRef175
P. Szulc. (2008) Pathophysiology and Diagnosis of Osteoporosis in Aging Men. IBMS BoneKEy 5:10, 370-380
CrossRef176
Tyler J. VanderWeele. (2008) The Sign of the Bias of Unmeasured Confounding. Biometrics 64:3, 702-706
CrossRef177
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka. (2008) Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancer—A New Standard?. European Urology 54:3, 528-542
CrossRef178
Juliette Allport. (2008) Incidence and prevalence of medication-induced osteoporosis: evidence-based review. Current Opinion in Rheumatology 20:4, 435-441
CrossRef179
Daniel A. Galvão, Nigel A. Spry, Dennis R. Taaffe, Robert U. Newton, John Stanley, Tom Shannon, Chris Rowling, Richard Prince. (2008) Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU International 102:1, 44-47
CrossRef180
Sharon H. Giordano, Yong-Fang Kuo, Zhigang Duan, Gabriel N. Hortobagyi, Jean Freeman, James S. Goodwin. (2008) Limits of observational data in determining outcomes from cancer therapy. Cancer 112:11, 2456-2466
CrossRef181
Robert U. Newton, Daniel A. Galvão. (2008) Exercise in Prevention and Management of Cancer. Current Treatment Options in Oncology 9:2-3, 135-146
CrossRef182
D A Galvão, K Nosaka, D R Taaffe, J Peake, N Spry, K Suzuki, K Yamaya, M R McGuigan, L J Kristjanson, R U Newton. (2008) Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer and Prostatic Diseases 11:2, 160-165
CrossRef183
Charles D Scales, Philipp Dahm. (2008) The critical use of population-based medical databases for prostate cancer research. Current Opinion in Urology 18:3, 320-325
CrossRef184
Scott M Gilbert. (2008) Shifting focus to cancer survivorship in prostate cancer: challenges and opportunities. Current Opinion in Urology 18:3, 326-332
CrossRef185
J Christopher Fritton, Elizabeth R Myers, Timothy M Wright, Marjolein CH van der Meulen. (2008) Bone Mass Is Preserved and Cancellous Architecture Altered Due to Cyclic Loading of the Mouse Tibia After Orchidectomy. Journal of Bone and Mineral Research 23:5, 663-671
CrossRef186
Gerhard Schreiber, Mirjana Ziemer. (2008) The aging male – diagnosis and therapy of late-onset hypogonadism. JDDG 6:4, 273-279
CrossRef187
Karine Briot, Christian Roux. (2008) Drug-induced osteoporosis: Beyond glucocorticoids. Current Rheumatology Reports 10:2, 102-109
CrossRef188
Noel W. Clarke. (2008) What Does Failure After Surgery or Radiation Mean?. European Urology Supplements 7:5, 410-415
CrossRef189
Jesús M. Fernández Gómez, Miguel Álvarez Múgica, Antonio Jalón Monzón, Jorge García Rodríguez. (2008) Efectividad de los bisfosfonatos en el cáncer de próstata avanzado. Medicina Clínica 130:12, 459-462
CrossRef190
Adam M Brufsky. (2008) Zoledronic acid for cancer therapy-induced and postmenopausal bone loss. Expert Opinion on Pharmacotherapy 9:6, 1013-1028
CrossRef191
T J Polascik. (2008) Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. Prostate Cancer and Prostatic Diseases 11:1, 13-19
CrossRef192
Jean-Pierre Droz, Agnieska Chaladaj. (2008) Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU International 101, 23-29
CrossRef193
Y. Yamada, S. Takahashi, T. Fujimura, H. Nishimatsu, A. Ishikawa, H. Kume, K. Tomita, T. Takeuchi, T. Kitamura. (2008) The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer. Osteoporosis International 19:3, 321-327
CrossRef194
John Hoogeveen, Eveline Van der Veer. (2008) Side Effects of Pharmacotherapy on Bone with Long-Acting Gonadorelin Agonist Triptorelin for Paraphilia. The Journal of Sexual Medicine 5:3, 626-630
CrossRef195
John M. Fitzpatrick. (2008) Management of localized prostate cancer in senior adults: the crucial role of comorbidity. BJU International 101, 16-22
CrossRef196
Ron S. Israeli, Christopher W. Ryan, Laura L. Jung. (2008) Managing Bone Loss in Men With Locally Advanced Prostate Cancer Receiving Androgen Deprivation Therapy. The Journal of Urology 179:2, 414-423
CrossRef197
Scott M. Gilbert, David C. Miller, Brent K. Hollenbeck, James E. Montie, John T. Wei. (2008) Cancer Survivorship: Challenges and Changing Paradigms. The Journal of Urology 179:2, 431-438
CrossRef198
B.L. Clarke. (2008) Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial. Yearbook of Endocrinology 2008, 223-226
CrossRef199
Celestia S Higano. (2008) Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?. Nature Clinical Practice Urology 5:1, 24-34
CrossRef200
M.R. Smith, S.B. Malkowicz, F. Chu, J. Forrest, D. Price, P. Sieber, K.G. Barnette, D. Rodriguez, M.S. Steiner. (2008) Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study. The Journal of Urology 179:1, 152-155
CrossRef201
Daniel E. Soto, Patrick W. McLaughlin. (2008) Combined Permanent Implant and External-Beam Radiation Therapy for Prostate Cancer. Seminars in Radiation Oncology 18:1, 23-34
CrossRef202
Sylvain Mimoun, Lucien Chaby. (2008) Le vieillissement masculin et ses multiples facettes. Champ psychosomatique 49:1, 73
CrossRef203
John T. Schousboe, Tamara Vokes, Susan B. Broy, Lynne Ferrar, Fergus McKiernan, Christian Roux, Neil Binkley. (2008) Vertebral Fracture Assessment: The 2007 ISCD Official Positions. Journal of Clinical Densitometry 11:1, 92-108
CrossRef204
Irwin Lee, Howard Sandler. (2008) Hormone Therapy and Radiotherapy for Intermediate Risk Prostate Cancer. Seminars in Radiation Oncology 18:1, 7-14
CrossRef205
Kathryn Bylow, Supriya G. Mohile, Walter M. Stadler, William Dale. (2007) Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?. Cancer 110:12, 2604-2613
CrossRef206
D A Galvão, D R Taaffe, N Spry, R U Newton. (2007) Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer and Prostatic Diseases 10:4, 340-346
CrossRef207
Meng-Yi Weng, Nancy E. Lane. (2007) Medication-induced osteoporosis. Current Osteoporosis Reports 5:4, 139-145
CrossRef208
José Manuel Olmos Martínez, Jesús González Macías. (2007) Osteoporosis tras la curación tumoral. Medicina Clínica 129:17, 669-676
CrossRef209
Preston C Sprenkle, Harry Fisch. (2007) Pathologic effects of testosterone deprivation. Current Opinion in Urology 17:6, 424-430
CrossRef210
J. J. Body, P. Bergmann, S. Boonen, Y. Boutsen, J. P. Devogelaer, S. Goemaere, J. Y. Reginster, S. Rozenberg, J. M. Kaufman. (2007) Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporosis International 18:11, 1439-1450
CrossRef211
Christopher S. Saigal, John L. Gore, Tracey L. Krupski, Janet Hanley, Matthias Schonlau, Mark S. Litwin, . (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:7, 1493-1500
CrossRef212
Bo Abrahamsen, Morten F. Nielsen, Peter Eskildsen, Jens Thorup Andersen, Steen Walter, Kim Brixen. (2007) Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU International 100:4, 749-754
CrossRef213
Tracey L. Krupski, Kathleen A. Foley, Onur Baser, Stacey Long, David Macarios, Mark S. Litwin. (2007) Health Care Cost Associated With Prostate Cancer, Androgen Deprivation Therapy and Bone Complications. The Journal of Urology 178:4, 1423-1428
CrossRef214
N. Koopmans, I.J. de Jong, A.J. Breeuwsma, E. van der Veer. (2007) Serum Bone Turnover Markers (PINP and ICTP) for the Early Detection of Bone Metastases in Patients With Prostate Cancer: A Longitudinal Approach. The Journal of Urology 178:3, 849-853
CrossRef215
Sue A. Brown, Theresa A. Guise. (2007) Cancer-associated bone disease. Current Osteoporosis Reports 5:3, 120-127
CrossRef216
C. Börgermann, G. Matnjani, T. Wiegel, S. Krege. (2007) Prostatakarzinom. Der Onkologe 13:9, 840-846
CrossRef217
Eric C. Nelson, Christopher P. Evans, Chong-Xian Pan, Primo N. Lara. (2007) Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. World Journal of Urology 25:4, 393-399
CrossRef218
Ellen F. T. Yee, Robert E. White, Glen H. Murata, Christine Handanos, Richard M. Hoffman. (2007) Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy. Journal of General Internal Medicine 22:9, 1305-1310
CrossRef219
G. S. Wilkinson, Y.-F. Kuo, J. L. Freeman, J. S. Goodwin. (2007) Intravenous Bisphosphonate Therapy and Inflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis. JNCI Journal of the National Cancer Institute 99:13, 1016-1024
CrossRef220
Christopher W. Ryan, Dezheng Huo, Kathryn Bylow, Laurence M. Demers, Walter M. Stadler, Tara O. Henderson, Nicholas J. Vogelzang. (2007) Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU International 100:1, 70-75
CrossRef221
Christopher W. Ryan, Dezheng Huo, James W. Stallings, Ronald L. Davis, Tomasz M. Beer, Laura T. McWhorter. (2007) Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy. Urology 70:1, 122-126
CrossRef222
G. Lümmen, H. Rübben, T. Schneider, H. Sperling. (2007) Prävention der Osteoporose – wichtig für den Urologen?. Der Urologe 46:6, 651-655
CrossRef223
Matthew R Smith. (2007) Androgen deprivation therapy for prostate cancer: new concepts and concerns. Current Opinion in Endocrinology, Diabetes and Obesity 14:3, 247-254
CrossRef224
Sue A Brown, Theresa A Guise. (2007) Drug Insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men. Nature Clinical Practice Urology 4:6, 310-320
CrossRef225
Bob Djavan. (2007) New Tools for the Urologist in the Management of Patients with Bone Metastases. European Urology Supplements 6:11, 689-694
CrossRef226
T. J. Wilt, K. E. Ensrud. (2007) The If's, And's, or But's Regarding Bisphosphonates for Prostate Cancer. JNCI Journal of the National Cancer Institute 99:10, 744-745
CrossRef227
Scott M. Gilbert, Rodney L. Dunn, John T. Wei. (2007) Re: Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer. The Journal of Urology 177:4, 1584-1585
CrossRef228
Jacques Planas, Juan Morote, Anna Orsola, Carlos Salvador, Enrique Trilla, Lluis Cecchini, Carles X. Raventós. (2007) The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU International 99:4, 812-816
CrossRef229
Julie N. Graff, Motomi Mori, Hong Li, Mark Garzotto, David Penson, Arnold L. Potosky, Tomasz M. Beer. (2007) Predictors of Overall and Cancer-Free Survival of Patients With Localized Prostate Cancer Treated With Primary Androgen Suppression Therapy: Results From the Prostate Cancer Outcomes Study. The Journal of Urology 177:4, 1307-1312
CrossRef230
Yu-Ming Liu, Cheng-Ying Shiau, Mei-Ling Lee, Pin-I. Huang, Chuen-Mei Hsieh, Pai-Hsuen Chen, Yi-Hsien Lin, Ling-Wei Wang, Sang-Hue Yen. (2007) The role and strategy of IMRT in radiotherapy of pelvic tumors: Dose escalation and critical organ sparing in prostate cancer. International Journal of Radiation Oncology*Biology*Physics 67:4, 1113-1123
CrossRef231
Juan Morote, Jacques Planas Morin, Anna Orsola, Jose M. Abascal, Carles Salvador, Enrique Trilla, Carles X. Raventos, Lluis Cecchini, Gloria Encabo, Jaume Reventos. (2007) Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer. Urology 69:3, 500-504
CrossRef232
Arto Mikkola, Jussi Aro, Sakari Rannikko, Mirja Ruutu, . (2007) Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy. The Prostate 67:4, 447-455
CrossRef233
Lawrence Drudge-Coates. (2007) Bone health: the effect of androgen deprivation therapy in prostate cancer patients. International Journal of Urological Nursing 1:1, 18-26
CrossRef234
Fred Saad, Cora N Sternberg. (2007) Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Nature Clinical Practice Urology 4, S3-S13
CrossRef235
Ugis Gruntmanis. (2007) Male Osteoporosis: Deadly, but Ignored. The American Journal of the Medical Sciences 333:2, 85-92
CrossRef236
Mack Roach, Alejandra Izaguirre. (2007) Goserelin acetate in combination with radiotherapy for prostate cancer. Expert Opinion on Pharmacotherapy 8:2, 257-264
CrossRef237
Axel Hegele, Hans Günther Wahl, Zoltan Varga, Selim Sevinc, Liseta Koliva, Andres Jan Schrader, Rainer Hofmann, Peter Olbert. (2007) Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU International 99:2, 330-334
CrossRef238
Manfred P. Wirth, Oliver W. Hakenberg, Michael Froehner. (2007) Antiandrogens in the Treatment of Prostate Cancer. European Urology 51:2, 306-314
CrossRef239
Grace Lu-Yao, Dirk F. Moore, John U. Oleynick, Robert S. DiPaola, Siu-Long Yao. (2007) Population Based Study of Hormonal Therapy and Survival in Men With Metastatic Prostate Cancer. The Journal of Urology 177:2, 535-539
CrossRef240
Michel B. Choueiri, Shi-Ming Tu, Li-Yuan Yu-Lee, Sue-Hwa Lin. (2007) The central role of osteoblasts in the metastasis of prostate cancer. Cancer and Metastasis Reviews 25:4, 601-609
CrossRef241
James A. Eastham. (2007) Bone Health in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. The Journal of Urology 177:1, 17-24
CrossRef242
F. Joly, S.M.H. Alibhai, J. Galica, A. Park, Q.-L. Yi, L. Wagner, I.F. Tannock. (2006) Impact of Androgen Deprivation Therapy on Physical and Cognitive Function, as Well as Quality of Life of Patients With Nonmetastatic Prostate Cancer. The Journal of Urology 176:6, 2443-2447
CrossRef243
Victor T. Chang, Nora Janjan, Subash Jain, Chi Chau. (2006) Regional Cancer Pain Syndromes. Journal of Palliative Medicine 9:6, 1435-1453
CrossRef244
Andrea L Harzstark, Charles J Ryan, Eric J Small. (2006) Bisphosphonate therapy for the treatment of skeletal complications in patients with prostate cancer. Aging Health 2:6, 943-954
CrossRef245
DANIEL A. GALV??O, KAZUNORI NOSAKA, DENNIS R. TAAFFE, NIGEL SPRY, LINDA J. KRISTJANSON, MICHAEL R. MCGUIGAN, KATSUHIKO SUZUKI, KANEMITSU YAMAYA, ROBERT U. NEWTON. (2006) Resistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients. Medicine & Science in Sports & Exercise 38:12, 2045-2052
CrossRef246
Shabbir M.H. Alibhai, Sven Gogov, Zishan Allibhai. (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review. Critical Reviews in Oncology/Hematology 60:3, 201-215
CrossRef247
Sandy Srinivas, Natalia Colocci. (2006) Bone Related Events in High Risk Prostate Cancer. The Journal of Urology 176:6, S50-S54
CrossRef248
Joshua H. Petit, Ming-Hui Chen, Marian Loffredo, Brenda Sussman, Andrew A. Renshaw, Anthony V. D'Amico. (2006) Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer 107:9, 2180-2185
CrossRef249
Nick Pavlakis, Dinesh Patel, Martin R Stockler, Nick Pavlakis. 2006. Bisphosphonates in early prostate cancer. .
CrossRef250
Jan M. Bruder, J.Z. Ma, N. Wing, J. Basler, D. Katselnik. (2006) Effects of Alendronate on Bone Mineral Density in Men with Prostate Cancer Treated with Androgen Deprivation Therapy. Journal of Clinical Densitometry 9:4, 431-437
CrossRef251
Noel W. Clarke. (2006) Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis. European Urology Supplements 5:17, 873-876
CrossRef252
HIDEYUKI AKAZA, YUKIO HOMMA, MICHIYUKI USAMI, YOSHIHIKO HIRAO, TOMOYASU TSUSHIMA, KIYOKI OKADA, MASAO YOKOYAMA, YASUO OHASHI, YOSHIO ASO, . (2006) Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU International 98:3, 573-579
CrossRef253
Christopher W. Ryan, Dezheng Huo, Laurence M. Demers, Tomasz M. Beer, Leo V. Lacerna. (2006) Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer. The Journal of Urology 176:3, 972-978
CrossRef254
Grace Lu-Yao, Dirk F. Moore, John Oleynick, Robert S. DiPaola, Siu-Long Yao. (2006) Use of Hormonal Therapy in Men With Metastatic Prostate Cancer. The Journal of Urology 176:2, 526-531
CrossRef255
Celestia Higano. (2006) Androgen Deprivation Therapy: Monitoring and Managing the Complications. Hematology/Oncology Clinics of North America 20:4, 909-923
CrossRef256
John T. Leppert, John S. Lam, Anthony W. Butch, Arie S. Belldegrun. (2006) The sensitivity of testosterone immunoassays and their role in monitoring antiandrogen therapy. Urologic Oncology: Seminars and Original Investigations 24:4, 277-278
CrossRef257
NICOLAS MOTTET, TOMMASO PRAYER-GALETTI, PETER HAMMERER, MICHAEL W. KATTAN, ULF TUNN. (2006) Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU International 98:1, 20-27
CrossRef258
Shabbir M.H. Alibhai, Sameera Rahman, Padraig R. Warde, Michael A.S. Jewett, Taha Jaffer, Angela M. Cheung. (2006) Prevention and management of osteoporosis in men receiving androgen deprivation therapy: A survey of urologists and radiation oncologists. Urology 68:1, 126-131
CrossRef259
V. B. Shahinian, Y.-F. Kuo, J. L. Freeman, J. S. Goodwin. (2006) Determinants of Androgen Deprivation Therapy Use for Prostate Cancer: Role of the Urologist. JNCI Journal of the National Cancer Institute 98:12, 839-845
CrossRef260
Fred Saad. (2006) The role of bisphosphonates in the management of prostate cancer. Current Oncology Reports 8:3, 221-227
CrossRef261
Scott M. Gilbert, James M. McKiernan. (2006) The Role of Bisphosphonates in Preventing Skeletal Complications of Hormonal Therapy. Urologic Clinics of North America 33:2, 191-199
CrossRef262
Jeffrey M. Holzbeierlein. (2006) Managing Complications of Androgen Deprivation Therapy for Prostate Cancer. Urologic Clinics of North America 33:2, 181-190
CrossRef263
Juan Morote, Anna Orsola, Jose M. Abascal, Jacques Planas, Enrique Trilla, Carles X. Raventos, Lluis Cecchini, Gloria Encabo, Jaume Reventos. (2006) Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression. The Journal of Urology 175:5, 1679-1683
CrossRef264
Timothy J. Daskivich, William K. Oh. (2006) Recent progress in hormonal therapy for advanced prostate cancer. Current Opinion in Urology 16:3, 173-178
CrossRef265
Kurt Miller. (2006) The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients. European Urology Supplements 5:7, 543-546
CrossRef266
Samir S Taneja, Matthew R Smith, James T Dalton, Sharan Raghow, Gary Barnette, Mitchell Steiner, Karen A Veverka. (2006) Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opinion on Investigational Drugs 15:3, 293-305
CrossRef267
Robert L Vessella, Theresa A Guise, Edward S Susman, Larry J Suva, Gregory A Clines, Scott L Kominsky, Kristy L Weber, John M Chirgwin, Laurie K McCauley, Wende Kozlow. (2006) Meeting report from skeletal complications of malignancy IV. BoneKEy-Osteovision 3:3, 15-42
CrossRef268
(2006) Abstracts. Cancer Investigation 24:s1, 5-64
CrossRef269
Matthew R. Smith, Simone Peart Boyce, Erick Moyneur, Mei Sheng Duh, Monika K. Raut, Jane Brandman. (2006) Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer. The Journal of Urology 175:1, 136-139
CrossRef270
Jan M. Bruder, Jennie Z. Ma, Joseph W. Basler, Michelle D. Welch. (2006) Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 67:1, 152-155
CrossRef271
Matthew R. Smith. (2006) Markers of bone metabolism in prostate cancer. Cancer Treatment Reviews 32, 23-26
CrossRef272
Matthew R. Smith, Simone Peart Boyce, Erick Moyneur, Mei Sheng Duh, Monika K. Raut, Jane Brandman. (2006) Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer. The Journal of Urology 175:1, 136???139
CrossRef273
KEVIN M. O'CONNOR, JOHN M. FITZPATRICK. (2006) Side-effects of treatments for locally advanced prostate cancer. BJU International 97:1, 22-28
CrossRef274
Robert E. Coleman. (2006) The role of bone markers in metastatic bone disease. Cancer Treatment Reviews 32, 1-2
CrossRef275
P LOEHRERSR. (2006) Risk of Fracture After Androgen Deprivation for Prostate CancerShahinian VB, Kuo Y-F, Freeman JL, et al (Univ of Texas, Galveston) N Engl J Med 352:154–164, 2005§. Yearbook of Medicine 2006, 185-185
CrossRef276
Mark S. Cooper, Neil J.L. Gittoes. (2005) Drug-induced bone disease. Adverse Drug Reaction Bulletin &NA;:235, 903-906
CrossRef277
Jennifer J Kelly, Arnold M Moses. (2005) Osteoporosis in men: the role of testosterone and other sex-related factors. Current Opinion in Endocrinology & Diabetes 12:6, 452-458
CrossRef278
Matthew R Smith. (2005) Therapy Insight: osteoporosis during hormone therapy for prostate cancer. Nature Clinical Practice Urology 2:12, 608-615
CrossRef279
Ariella Kelman, Nancy E. Lane. (2005) The management of secondary osteoporosis. Best Practice & Research Clinical Rheumatology 19:6, 1021-1037
CrossRef280
Thomas J. Polascik, Robert W. Given, Charles Metzger, Sydney R. Julian, James C. Vestal, Gary S. Karlin, Craig S. Barkley, David L. Bilhartz, Laura T. McWhorter, Leo V. Lacerna. (2005) Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 66:5, 1054-1059
CrossRef281
James W Denham, Allison Steigler, David S Lamb, David Joseph, Hedy Mameghan, Sandra Turner, John Matthews, Ian Franklin, Chris Atkinson, John North, Michael Poulsen, David Christie, Nigel A Spry, Keen-Hun Tai, Chris Wynne, Gillian Duchesne, Olga Kovacev, Catherine D'Este. (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. The Lancet Oncology 6:11, 841-850
CrossRef282
Hang Lee, Katelyn McGovern, Joel S. Finkelstein, Matthew R. Smith. (2005) Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104:8, 1633-1637
CrossRef283
Pierre D Delmas. (2005) The use of bisphosphonates in the treatment of osteoporosis. Current Opinion in Internal Medicine 4:5, 512-516
CrossRef284
V. Jenkins, L. Fallowfield, T. Edginton, H Payne, E. Hamilton. (2005) Preferences of hxealthy men for two different endocrine treatment options offered for locally advanced prostate cancer*. Current Medical Research and Opinion 21:9, 1329-1335
CrossRef285
Hermann M. Behre. (2005) Long-Term Morbidity of Late-Onset Hypogonadism. European Urology Supplements 4:6, 10-15
CrossRef286
Raisz, Lawrence G., . (2005) Screening for Osteoporosis. New England Journal of Medicine 353:2, 164-171
Full Text287
Jan M. Bruder. (2005) Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy. Current Urology Reports 6:3, 157-158
CrossRef288
Michael R. McClung. (2005) The relationship between bone mineral density and fracture risk. Current Osteoporosis Reports 3:2, 57-63
CrossRef289
Vahakn B. Shahinian, Yong-fang Kuo, Jean L. Freeman, Eduardo Orihuela, James S. Goodwin. (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:8, 1615-1624
CrossRef290
Fred Saad. (2005) Zoledronic acid: past, present and future roles in cancer treatment. Future Oncology 1:2, 149-159
CrossRef291
(2005) Androgen deprivation therapy and risk of bone fracture. Nature Clinical Practice Urology 2:2, 65-65
CrossRef292
E. Seeman. (2005) Clinical and Basic Research Papers - January 2005 Selections. International Bone and Mineral Society Knowledge Environment 2:2, 1-6
CrossRef293
Eeva Salminen, M Ala-Houhala, J Korpela, M Varpula, S. L. Tiitinen, J. M. Halleen, H. K Väänänen. (2005) Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncologica 44:7, 742-747
CrossRef
